TORONTO, Jan. 6 /CNW/ - Health Canada has approved ALDARA(TM) (imiquimod) Cream, 5%, a topical prescription medication for the treatment of superficial basal cell carcinoma (sBCC) - a form of non-melanoma skin cancer. ALDARA is the first new treatment for this type of cancer to be approved in Canada in close to 30 years and is the first in a new class of medications called immune response modifiers. The medication works by triggering the body's immune system to find and kill mutated cells on the outer layer of the skin.